

Supplementary material 7 - Extracted costs for postnatal care

Activity Costed	Economic Evaluations for	Review Articles	Primary research articles		
	National Guidelines		Unit cost reported	Range	Mean (SD)
Maternal inpatient stay on postnatal ward	£676.44 / day [1], £431.56 / day [2]	£74.62 for average postnatal stay [3], £459.63/day [4]	£330.84 / day [5], £549.09 / day [6], £112.95 / day [7], £870.10 / day [8], £1,289.57 / admission [9], £488.42/day [10] £103.00 - £757.00/day [11], £407.83 / day [12], £1,406.39 for average length of stay (<3 days) [13], £754.14 / standard 36-hour postnatal stay [14], £470.19 / day [15], £20.47 / hour (staff costs only) [16], £447.12 / day [17]	£103.00 – £870.10	£471.12 (£211.26) Full costs only included.

Activity Costed	Economic Evaluations for National Guidelines	Review Articles	Primary research articles		
			Unit cost reported	Range	Mean (SD)
Maternal inpatient stay in HDU	£936.17 / day [1], £636.44/day [2]		£804.38 / day [5], £95.12 for 4 hours [7], £712.17 / day [18], £700.37/day [10], £890.00 / day [11], £587.40 / day (level 1), £734.52 / day (level 2) [15], £2,150.63 for first 2 days [17]	£570.72 - £1075.32	£764.75 (£277.20)
Maternal inpatient stay in ITU	£1,737.28 / day [1]	Not costed	£1,729.56 / day [19], £1,444.56 / day [6], £665.82 / day [7], £1,367.21 / day [18], £1,449.00 / day [11], £924.14 / day [15], £3,722.01 for first 2 days [17]	£665.82 - £1,861.01	£1,397.32 (£606.35)

1. National Institute for Health and Care Excellence, *Hypertension in pregnancy: diagnosis and management*. 2011: p. 1-51.
2. National Institute for Health and Care Excellence, *Intrapartum Care for healthy women and babies. Clinical Guideline CG 190*. . 2014.

3. Thomas, C.M. and S. Cameron, *Can we reduce costs and prevent more unintended pregnancies? A cost of illness and cost-effectiveness study comparing two methods of EHC*. BMJ Open, 2013. **3**(12): p. e003815.
4. Gallos, I., et al., *Uterotonic drugs to prevent postpartum haemorrhage: a network meta-analysis*. Health Technol Assess, 2019. **23**(9): p. 1-356.
5. Petrou, S., et al., *Cost-effectiveness analysis of prostaglandin E2 gel for the induction of labour at term*. BJOG, 2011. **118**(6): p. 726-34.
6. Eddama, O., et al., *Study of progesterone for the prevention of preterm birth in twins (STOPPIT): findings from a trial-based cost-effectiveness analysis*. Int J Technol Assess Health Care, 2010. **26**(2): p. 141-8.
7. Schroeder, E., et al., *Cost effectiveness of alternative planned places of birth in woman at low risk of complications: evidence from the Birthplace in England national prospective cohort study*. BMJ, 2012. **344**: p. e2292.
8. Ussher, M., et al., *The London Exercise And Pregnant smokers (LEAP) trial: a randomised controlled trial of physical activity for smoking cessation in pregnancy with an economic evaluation*. Health Technol Assess, 2015. **19**(84): p. vii-xxiv, 1-135.
9. Walker, K.F., et al., *Labour induction near term for women aged 35 or over: an economic evaluation*. BJOG, 2017. **124**(6): p. 929-934.
10. van der Nelson, H.A., et al., *Carbetocin versus oxytocin for prevention of post-partum haemorrhage at caesarean section in the United Kingdom: An economic impact analysis*. Eur J Obstet Gynecol Reprod Biol, 2017. **210**: p. 286-291.
11. Bick, D., et al., *A multicentre, randomised controlled trial of position during the late stages of labour in nulliparous women with an epidural: clinical effectiveness and an economic evaluation (BUMPES)*. Health Technol Assess, 2017. **21**(65): p. 1-176.
12. Campbell, H.E., et al., *Healthcare and wider societal implications of stillbirth: a population-based cost-of-illness study*. BJOG, 2018. **125**(2): p. 108-117.
13. Orlovic, M., et al., *Estimating the incidence and the economic burden of third and fourth-degree obstetric tears in the English NHS: an observational study using propensity score matching*. BMJ Open, 2017. **7**(6): p. e015463.
14. Bowers, J. and H. Cheyne, *Reducing the length of postnatal hospital stay: implications for cost and quality of care*. BMC Health Serv Res, 2016. **16**: p. 16.
15. Khan, K.S., et al., *A randomised controlled trial and economic evaluation of intraoperative cell salvage during caesarean section in women at risk of haemorrhage: the SALVO (cell SALVage in Obstetrics) trial*. Health Technol Assess, 2018. **22**(2): p. 1-88.
16. Luni, Y., et al., *A prospective cohort study evaluating the cost-effectiveness of carbetocin for prevention of postpartum haemorrhage in caesarean sections*. J Obstet Gynaecol, 2017. **37**(5): p. 601-604.
17. Waugh, J., et al., *Spot protein-creatinine ratio and spot albumin-creatinine ratio in the assessment of pre-eclampsia: a diagnostic accuracy study with decision-analytic model-based economic evaluation and acceptability analysis*. Health Technol Assess, 2017. **21**(61): p. 1-90.
18. Coomarasamy, A., et al., *PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation*. Health Technol Assess, 2016. **20**(41): p. 1-92.
19. Jit, M., et al., *The cost-effectiveness of vaccinating pregnant women against seasonal influenza in England and Wales*. Vaccine, 2010. **29**(1): p. 115-22.